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Abstract
Background: Microglia, the macrophages of the brain, have been implicated in the causes of neurodegenerative
diseases and display a loss of function during aging. Throughout life, microglia are replenished by limited
proliferation of resident microglial cells. Replenishment by bone marrow-derived progenitor cells is still under
debate. In this context, we investigated the differentiation of mouse microglia from bone marrow (BM) stem cells.
Furthermore, we looked at the effects of FMS-like tyrosine kinase 3 ligand (Flt3L), astrocyte-conditioned medium
(ACM) and GM-CSF on the differentiation to microglia-like cells.
Methods: We assessed in vitro-derived microglia differentiation by marker expression (CD11b/CD45, F4/80), but
also for the first time for functional performance (phagocytosis, oxidative burst) and in situ migration into living
brain tissue. Integration, survival and migration were assessed in organotypic brain slices.
Results: The cells differentiated from mouse BM show function, markers and morphology of primary microglia and
migrate into living brain tissue. Flt3L displays a negative effect on differentiation while GM-CSF enhances
differentiation.
Conclusion: We conclude that in vitro-derived microglia are the phenotypic and functional equivalents to primary
microglia and could be used in cell therapy.
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Background
Microglias constitute about 10% of the cell population
of the brain and represent the most important first
immune defense of the CNS. They are phagocytic, cyto-
toxic, antigen-presenting cells which promote brain tis-
sue repair after injury [1]. Primary microglia differ from
other blood macrophages in the expression levels of
markers like CD11b/CD45low/high [2], CD68 low/high
[3] and substance P levels [4]. Because of the overlap in
markers there is an ongoing discussion about the dis-
tinction between dendritic cells, macrophages and
microglia. The regulation of marker levels and activity
has led to the proposition that microglia could be
immature or resting macrophages [5]. However, there is
a lack of correlation between marker expression and
actual functional capacity, which is the most important
hallmark for therapeutic use. Microglia in the brain
normally display a quiescent state in which phagocytosis,
immune response and migration are down-regulated
and the microglia show a ramified morphology with
long processes [6]. Microglia react to inflammation by
switching to an activated state and taking on an amoe-
boid morphology [7]. They migrate towards sites of
injury and lesion and extracellular debris such as amy-
loid-b plaques [8]. An important function of microglia is
the “oxidative burst” - a sudden spike in reactive oxygen
species (ROS) levels generated by the stimulation of the
NADPH oxidase. This ROS production is accompanied
by the release of other factors, including lysosomal pro-
teases. This mechanism, often interpreted as a ‘defense’
response that can protect the brain from pathogens, is a
characteristic feature of microglia [9,10]. Microglia are
thought to originate from the yolk sac during embryo-
genesis [11] and are replenished by local proliferation
throughout adult life. The supplementation by progeni-
tor cells from the bone marrow is controversial
[1,11,12]. Bone marrow-derived microglia can be
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observed in the brain after systemic transplantation [13].
While BM chimeras have shown BM-derived microglia
[14], other findings indicate that without irradiation no
invasion is observable in the time frame of 1-2 months
[15,16]. But also in transplantations without irradiation
intravenously injected hematopoietic stem cells have
been observed to migrate to the brain, differentiate into
microglia and reduce infarct size [17]. The maturation
of progenitors to microglia occurs under the influence
of factors secreted by astrocytes [18]. Both local and
peripheral replenishment do not seem to suffice to pre-
vent the slow deterioration of the microglia cell popula-
tion and function with age [19,20]. In human Alzheimer
patients microglia associated with tau tangles were
found to be dystrophic, which might precede neurode-
generation [21]. In old rats there have been indications
that the proliferation of microglia after injury is stronger
than in young rats [22]. In vitro, proliferating rat micro-
glia have been reported to undergo telomere shortening
[23] and aged microglia of several species have been
observed to loose their ability to perform normal micro-
glia functions [19,20,24-28]. These findings support the
hypothesis of a slow deterioration of microglia as a con-
tribution to the onset of neurodegeneration [20,21].
The maturation of progenitors to microglia occurs
under the influence of factors secreted by astrocytes
[16]. Both local and peripheral replenishment do not
seem to suffice to prevent the slow deterioration of
microglia cell population and function with age [17,18].
The resident microglia are suspected to reach replicative
senescence during aging [18]. Microglia have been dif-
ferentiated in vitro from peripheral blood monocytes
[4,18] and from embryonic stem cells [29]. In this con-
text, we focus on differentiating microglia from bone
marrow. This approach was first demonstrated by Ser-
vet-Delprat et al. [30], who obtained 20% cells with
microglia-like morphology and marker expression
(CD115+, CD11b+, F4/80+, CD80 low, CD86-) after cul-
turing mouse BM cells in Flt3L for 11 days and then
mixing the cell-containing supernatant with astrocyte-
conditioned medium for 6 days. However, since the use
of Flt3L was not controlled in that protocol, its role as a
factor in microglia differentiation remained unclear.
Davoust et al. [31] used a similar protocol but signifi-
cantly shorter culture times and no Flt3L to obtain
CD11b +, CD45 +, MHCII -, B220 low, CD34+, and
CD86 low cells from mouse BM (the percentage yield is
not reported). The success of microglial cell differentia-
tion has been mostly judged by measurement of the
expression of markers and the morphology of the differ-
entiated cells. It remained unclear to what extent in
vitro-derived microglia-like cells share the functional
capacities of original microglia. To address this question,
we followed the protocol of Servet-Delprat et al. [30]
(with and without Flt3L), measured phagocytosis and
oxidative burst as hallmarks of microglial function and
tested the ability to survive and migrate in brain tissue.
Results
Surface marker expression
Untreated bone marrow cells showed significantly
increased CD11b/CD45 expression after 17 days in cul-
ture. The same was observed in cultures treated with
ACM/GM-CSF. Non-adherent BM cells treated with
ACM/GM-CSF and whole bone marrow and cultivated
for 17 days are observed in the same region as primary
microglia in the flow cytometry plots. Flt3L has an
adverse effect on differentiation, leading to low levels of
CD11b/CD45-positive cells in all Flt3L-supplemented
samples.
The frequency of F4/80+ cells already increased signif-
icantly in whole bone marrow after 7 days and also after
17 days, as compared to fresh bone marrow. The sup-
plementation of Flt3L or Flt3L/ACM/GM-CSF resulted
in significantly lower F4/80+ cell numbers while the sole
addition of ACM/GM-CSF yielded high numbers of F4/
80+ cells very similar to the CD11b/CD45 cell popula-
tions (Figure 1, Table 1).
Time course of marker expression
The frequency of CD11b+/CD45+ and F4/80+ cells in
whole bone marrow rose steadily and significantly with
extension of culture time (Figure 2, Table 1). The sup-
plementation of ACM/GMCSF to the non-adherent BM
cells increased CD11b+/CD45+ and F4/80+ cells over
time; however, the increase was significantly slower and
only reached the same level as un-supplemented bone
marrow at day 17 (it therefore seems that ACM/GM
does not have an improvement effect). The supplemen-
tation of Flt3L resulted in a lower frequency of CD11b
+/CD45+ and also F4/80+ (Figure 2, Table 1). The
addition of ACM/GMCSF significantly increased the
medians of CD11b expression after 10 days (Figure 2,
Table 1).
Phagocytic activity and oxidative burst
Whole bone marrow cultured over a period of 7, 10 or
17 days showed a constant significantly higher percen-
tage of phagocytic cells compared to fresh bone marrow
(Figure 3A). Supplementation with ACM/GM-CSF
increased the number of phagocytic cells significantly
compared to unsupplemented bone marrow at day 17.
Flt3L supplementation significantly inhibited the differ-
entiation towards phagocytizing microglia, even when
ACM/GM-CSF was added. We observed the same
changes in the amount of microglia performing oxida-
tive burst (Figure 3b); however, the differences were less
pronounced.
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Cell morphology
Primary microglia show long processes and rod-shaped
cells (Figure 4A). Unsupplemented bone marrow cells
had mixed morphologies during the whole cultivation
time (Figure 4C, D). The cells supplemented with ACM/
GM-CSF are more homogenous and show high ramifi-
cation (Figure 4F). Cells treated with Flt3L alone or in
the presence of Flt3L and ACM/GM-CSF both have a
more fibroblastic morphology with no resemblance to
microglia (Figure 4H).
Migration in organotypic brain slices
Whole brain slices were cultured for 10 days to mini-
mize surface damage before differentiated microglia pre-
labeled with 3,3’-dioctadecyloxacarbocyanine perchlorate
(DiO) were added on top of the brain slices. The slice
Figure 1 Flow cytometric analysis of adherent? BM cells. (A) Flow cytometric analysis of adherent? BM cells on CD11b/CD45 expression (n =
3) following culture in vitro for certain period of time. Representative scatter plots of CD11b/CD45 labeled differentiated cells and primary
microglia, fresh bone marrow and an isotype control. (B) Flow cytometric analysis of adherent? BM cells on their F4/80 expression (n = 3).
Representative histogram plots of F4/80 labeled differentiated cells, primary microglia and fresh bone marrow. Isotype control gray, F4/80 labeled
cells black. *** = P < 0.001, ** = P < 0.01, * = P < 0.05.
Table 1 Flow cytometric analysis of the cells differentiated and analyzed for microglia specific markers
Protocol Supplementation CD11b
percent
CD11b
median
F4/80
percent
F4/80
median
CD11b/CD45
percent
Cells in microglia
gate
BM 0 days 20+/-9.5 2+/-0.7 2.3+/-0.1 1.2+/-0.1 20+/-9.5 6,7+/-3,6
BM 7 days 51,2+/-15,5 7,8+/-3,5 55,9+/-5,3 4,4+/-0,6 54,7+/-15,0 54+/-19,7
BM 10 days 67,3+/-2,8 8,8+/-1,5 59,8+/-3,3 4,3+/-0,3 72,8+/-2,9 70,3+/-4,1
BM 17 days 68,4+/-0,6 13,8+/-0,4 64,5+-0,6 3,6+/-0,1 70+/-0,5 84,2+/-0,5
Sup. BM day
11
71,7+/-3,6 9,5+/-1,3 40,5+/-5,1 2,7+/-0,4 71,7+/-3,6 62,7+/-6,5
Sup. BM day
11
Flt3L 35,8+/-12,9 3,6+/-2,1 6,8+/-1,3% 1+/-0,2 35,8+/-12,9 20,1+/-18,8
Protocol 2 ACM/GM-CSF 85,6+/-1,5 23,3+/-2,9 66,4+/-1,7 3+/-0,3 89,1+/-1,5 90+/-1,7
Protocol 3 Flt3L/ACM/GM-
CSF
39,1+/-8,1 2+/-0,3 18,8+/-3,1 1,3+/-0,2 46,6+/-8,0 9,9+/-2,7
Protocol 4 Flt3L 8,2+/-4,1 1+/-0,0 10,7+/-5,1 1,1+/-0,1 15,5+/-4,1 5,1+/-0,5
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Figure 2 Time course of CD11b/CD45 and F4/80 expression of untreated and cytokine treated BMC (n = 3). Time course of CD11b and
F4/80 medians. Significant changes are denoted with respect to freshly isolated BMC on day 0. *** = P < 0.001, ** = P < 0.01, * = P < 0.05.
Figure 3 Phagocytosis and Oxidative burst of differentiated cells. (A) Phagocytosis of differentiated cells and fluorescence microscope
picture of phagocytosis of non adherent BM cells differentiated with ACM/GM-CSF (n = 3). Arrows indicate the same cell in bright field and
fluorescence picture. Fluorescence images were taken with a Zeiss Axio Observer at 200× (left) and 400× (right) magnification. (B) Oxidative
burst of differentiated cells, representative histogram plot of inactive (open histogram) and PMA activated (red histogram) cells (n = 3). The shift
between un-treated and PMA treated microglia was measured as quotient between medians of treated and untreated cells (Fluorescence signal
noise ratio - FSN). Cells with no shift are based at 1 and higher numbers represent cell populations which did show ROS production. Light
microscope picture of NBT reduction of non adherent BM cells supplemented with ACM/GM-CSF. Arrows indicate one cell with dark blue NBT
precipitate and one cell without precipitate. The picture was taken with a Leica DM IL at 20× magnification. *** = P < 0.001, ** = P < 0.01, * = P
< 0.05.
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was counterstained with propidium iodide (PI) to visua-
lize dead cells. Reconstructed confocal images were
either top-down or showing a lateral view of the slice.
Microglia were observed over a period of 10 days and
found to survive and proliferate (Figure 5A-C, dead cells
deliberately included for reference). Over the course of
3 days, ACM/GM-CSF-supplemented BMC migrated
into the surface of the brain slices as deep as 50 μm
(Figure 5D-F). Cells of all protocols migrated up to 30
μm into the slice after 10 days while dead cells stayed
on top of the tissue (Figure 6A-D). Several cells
migrated up to 120 μm (160 μm confocal microscope
scan depth). Cells supplemented with Flt3L have the
same fibroblastic morphology as in the in vitro cultures
(Figure 6B) while additional supplementation with
ACM/GM-CSF resulted in round and amoeboid cells as
well as fibroblastic cells (Figure 6C). Cells supplemented
solely with ACM/GM-CSF almost exclusively showed
round cell morphology (Figure 6D). Cells of whole bone
marrow were round but larger than the ACM/GM-CSF-
supplemented cells after 7 days and did not migrate
more than 30 μm into the surface of the brain tissue
(Figure 6A).
Discussion
We investigated the differentiation and function of
microglia from bone marrow (BM) stem cells using
ACM and GM-CSF with and without Flt3L. As opposed
to M-CSF used by Davoust et al. [31], we used GM-CSF
as this is reported to expand primary microglia more
successfully than M-CSF [32,33]. Primary microglia have
been characterized as CD11b+/CD45low and distin-
guished from primary macrophages on the basis of their
CD45 expression level [2]. The in vitro-differentiated
microglia derived in this manner generally show marker
expression levels similar to those of primary microglia.
It is known that ACM treatment of BM cells can pro-
duce cells with markers for microglia [30]. However,
such cells have not been further characterized with
respect to phagocytic capacity and migration behavior
inside the brain or tested for the microglia-typical oxida-
tive burst. Here we demonstrate that BMC cultured in
the presence of ACM and GM-CSF show phagocytosis
and oxidative burst activity typical of microglia. The
cells also had long and branched processes similar to
primary microglia. Flt3L supplementation diminished
the functional markers and microglia-like morphology.
Thus, among the parameters tested here, the ‘optimal’
protocol for in vitro differentiation of microglia relies on
ACM, GM-CSF without Flt3L. Interestingly, we find
that even unsupplemented BM contains a subpopulation
positive for microglial markers (CD11b/CD45, F4/80)
and that this population is more dominant after 17 days
of differentiation. However, we find that microglia-like
Figure 4 Representative light microscope pictures of differentiated cells. Images were taken with a Leica DM IL at 200× magnification.
BMC: Whole bone marrow cells. Fluorescence picture of an Iba-1 stained microglia in a brain slice (B) was taken with an Axio Imager A1 (Zeiss)
at 63× magnification.
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Figure 5 Coculture with living brain slices. Differentiated ACM/GM-CSF treated BMC were labeled with DIO and seeded on brain slices on
day 9. Counterstaining with propidium iodide was used to assess cell survival. After 1, 2, 3, 6 and 10 days slices were scanned with a Leica
Microsystems TCS SP2 confocal microscope to assess survival of seeded cells and their migration into the tissue. Arrows indicate single cells that
have already migrated through the surface after 2 days. Magnification was 100x and scanning depth was 160 μm.
Figure 6 Differentiated cells of all protocols were labeled with DIO and seeded on brain slices on day 9. After 10 days coculture slices
were propidium iodide stained and scanned with a Leica Microsystems TCS SP2 confocal microscope to measure cell survival and their
migration. Arrows indicate several cells that have migrated deeper into the brain tissue. The images were taken at 100× magnification and the
brain slices were scanned to a depth of 160 μm.
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cells derived from BM without any supplementation dis-
play only low phagocytosis and oxidative burst levels
compared to ACM/GM-CSF-supplemented cells. Gener-
ally, unsupplemented bone marrow cultures show mixed
cell morphologies whereas supplemented cultures are
prone to display more homogeneous, branched cell
types. Flt3L has been used for the sequential differentia-
tion of BM cells presumably because it improves hema-
topoietic stem cell (HSC) survival in vitro [30] and in
vivo [34]. Servet-Delprat et al. only investigated Flt3L-
supplemented cells and did not consider unsupplemen-
ted cells. The group estimated 20% microglia from the
number of ramified cells, which is confirmed by our
results for ACM, GM-CSF, Flt3L-supplemented cells.
However, much higher functional microglia ‘yield’ can
be obtained in the absence of Flt3L. In fact, we demon-
strate that supplementation with Flt3L diminishes
microglia differentiation: where Flt3L is added alone or
in combination with ACM, GM-CSF, the number of
cells showing microglial markers as well as the capacity
for brain migration, phagocytosis and oxidative burst
decreases. The differentiation protocols investigated
here rely on using the supernatant at day 11 to select
for non-adherent HSC and then culturing it in the pre-
sence of ACM for another 6 days. The tactic here is to
first obtain a relatively pure HSC population which then
partially differentiates into adherent microglia. Flt3L has
been shown to expand HSC and transiently increase
adhesion of HSC in culture and it might play a role in
mobilization of HSC into the blood stream [35]. There-
fore, the amount of microglia progenitor cells in the day
11 supernatant bone marrow culture might be decreased
or the differentiation might be delayed. In addition,
Flt3L combined with GM-CSF has been shown to
enhance dendritic cell differentiation [36]. This fact is
supported by work with Flt3L knockout mice where
levels of dendritic cells are increased and numbers of
myeloid cells, the progenitors of microglia, are decreased
[37]. These factors may explain why Flt3L supplementa-
tion yields a lower count in functional in vitro-derived
microglia.
The microglial cell population is known to be hetero-
geneous and to overlap with dendritic cell-like popula-
tions in the brain [38]. The various procedures
employed for microglial differentiation might result in
distinct subpopulations or activation states. The choice
of the protocol might have a substantial impact on the
effect transplanted cells will have in vivo. This is espe-
cially important because different subsets of microglia
have been linked to tolerance induction or immune
reaction [39].
In co-cultures with organotypic brain slices the micro-
glia-like cells survived and proliferated for at least 10
days. It is known that the majority of primary microglia
or BV2 cells only migrate over the surface layer of brain
tissues under non-inflammatory conditions [40,41] while
a subpopulation migrates into the tissue. Directed
migration towards sites of injury induced by NMDA on
the surface of brain slice cultures has been observed for
primary microglia [41]. The damaged surface of the
brain slice cultures even attracts slice-internal microglia,
which showed directed migration to the surface [40].
This is supported by our results: Most cells migrate into
the brain slice tissue superficially while in vitro-derived
(ACM/GM-CSF, but without Flt3L) microglia migrated
deepest into the tissue and showed both amoeboid and
rounded morphologies suggesting an activated state.
The microglial cell population is known to overlap
with dendritic cell-like populations in the brain [38].
Dendritic cells differentiate from monocytes and mature
by exposure to antigens or under inflammatory condi-
tions [38]. There is evidence that cells showing an
immature dendritic phenotype can differentiate from
microglia under the influence of GM-CSF [38]. At the
same time, dendritic cells can be differentiated to micro-
glia-like cells which inhibit T cell proliferation induced
by mature dendritic cells [42]. In the current study,
microglia were differentiated using ACM and GM-CSF.
There is evidence that cells showing an immature den-
dritic phenotype can differentiate from microglia under
the influence of GM-CSF [38]. At the same time, den-
dritic cells can be differentiated to microglia like cells
which inhibit T cell proliferation induced by mature
dendritic cells [42]. Dendritic cells can act both tolero-
genic and immunogenic, depending on their maturation
state [43]. CD11c-positive microglia have been observed
to acquire immature dendritic cell phenotypes in models
of acute experimental autoimmune encephalomyelitis
(EAE) and to be part of the antigen-presenting cells
responsible for the disease [5]. The risk in using in
vitro-differentiated microglia in a therapy is that these
cell populations might contain a dendritic cell-like sub-
population expressing CD11c, which can stimulate an
autoimmune inflammation within the CNS [44]. This
might lead to the development of an autoimmune
phenotype.
It was one of our reasons for performing a functional
analysis on our in vitro-differentiated microglia that it
was described in the literature that the microglial subpo-
pulations displaying similarities to dendritic cells and
expressing CD11c (and other dendritic markers) do not
contain any phagocytic vacuoles [38]. Our cells are
selected for a highly phagocytic activity. This is an addi-
tional feature required to potentially clear protein aggre-
gates like amyloid plaques from the brain parenchyma,
but would also avoid the transplantation of autoim-
mune-inducing microglia. A risk still persists, as it was
shown that CD11b-positive microglia can produce cells
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with dendritic features which can acquire the antigen-
presenting activities after activation [44]. However, den-
dritic cells can act both immunogenic and tolerogenic,
depending on their maturation state [43]. This could be
beneficial for reducing transplant rejection [43] or used
to treat autoimmune inflammation, for example in acute
experimental autoimmune encephalomyelitis [5,45].
Transplantation of human microglia in ischemic brains
modulates inflammation and reduces neuronal apoptosis
[46]. Microglia provide neuroprotection in hippocampal
slice cultures while lipopolysaccharide-stimulated micro-
glia do not [47]. The various procedures employed for
microglial differentiation might result in distinct activa-
tion or differentiation states. The choice of the protocol
and the composition of the cells might have a substan-
tial impact on the effect transplanted cells will have in
vivo.
Conclusion
The in vitro-differentiated cells correspond to primary
microglia in phenotype and function. The importance of
microglia in degenerative diseases makes them an inter-
esting target for therapeutic approaches. If neurodegen-
erative diseases occur in part due to the age-dependent
deterioration of the microglial cell population number
and/or function, functional microglia supplementation
could have beneficial effects. For example, injection of
primary microglia into the brain of rats led to an
increased amyloid beta clearance [48]. Furthermore, the
suspected ability of microglial precursors to cross the
blood-brain barrier and to seek out sites of neuroinflam-
mation renders them potentially useful drug delivery
vehicles [49]. In vitro-derived microglia will need to
demonstrate the functional capacity of ‘real’ microglial
cells and our research makes some contributions to this
aim. However, extensive further tests will be required
before such cells are deemed suitable and safe for
transplantation.
Methods
Animals
C57BL/6 mice from the MEZ of the University of Leip-
zig and Charles River (Sulzfeld, Germany) were used as
sources for bone marrow, primary microglia and orga-
notypic brain slices in accordance with local animal
ethics permissions.
Isolation of bone marrow and cell culture
Bone marrow was obtained by centrifugation of femora
and tibiae. Isolated bone marrow cells were cultured at
a density of 107 cells in a 60 mm petri dish in 5 ml of
Dulbecco’s minimal essential medium (DMEM)/low glu-
cose (Hyclone Laboratories Inc.), supplemented with
10% fetal calf serum (FCS -Invitrogen) and 100 units/ml
Penicillin, 100 μg/ml Streptomycin.
Astrocyte-conditioned medium
Astrocyte-conditioned medium was produced by incu-
bating medium (DMEM/10% FCS) for 24 h with pri-
mary mouse astrocyte cultures [16].
Isolation of primary microglia
Primary microglia were isolated from brains of 1-3 day
old mice. The meninges was removed and the whole
brain was titrated in DMEM/10% FCS and Pen/Strep.
The resulting cell and tissue suspension of 3 brains was
cultured in a poly L-lysine-coated culture flask. After 24
h, the supernatant was removed from the cell culture
and new medium was added. After 7 days, 50% of the
culture medium was changed. At 14 days, microglia
were removed by gentle shaking [50].
Differentiation towards microglia-like cells
Experiment set 1
Whole bone marrow (107 cells) was cultivated over the
time periods of 7, 10 and 17 days in 10 ml DMEM/10%
FCS in a 60 mm petri dish and analyzed for certain cell
surface markers at these time points. When cells were
cultured for longer than 10 days, 50% of medium was
replaced at day 10.
Experiment set 2
Whole bone marrow (107 cells) was cultured for 11 days
in a 90 mm petri dish in either plain DMEM/10% FCS
or DMEM/10% FCS supplemented with 5 ng/ml Flt3L
(noFlt3L and Flt3L groups, respectively). After 11 days,
cells of both groups (with and without Flt3L) were ana-
lyzed for surface markers and non-adherent cells were
further cultured for a period of 6 days. To this end, cells
from 2 petri dishes were aspirated, transferred to a new
60 mm petri dish and cultured in DMEM/10% FCS sup-
plemented with 50% ACM and 20 ng/ml GM-CSF
(noFlt3L and Flt3L + suppl., groups); or supplements
were omitted for Flt3L group (Flt3L - suppl. group).
Flow cytometry
The differentiated cells were tested for the surface mar-
kers F4/80, CD11b, CD45 and CD11b/CD45 double
expression. The cells were trypsinized, centrifuged at
300 g for 5 min and fixed in 4% paraformaldehyde.
They were washed with phosphate buffered saline (PBS).
Afterwards, cells were incubated for 2 h at 4°C with
CD11b (1:250) or F4/80 (1:250) antibody (both Alexa
488-labeled, eBioscience) or with CD45 (1:100) antibody
(PE-labeled, eBioscience). The incubated cells were
washed again and fluorescence was measured with a
Beckmann Coulter FC 500.
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Phagocytosis
Phagocytic activity of the differentiated cells was mea-
sured by the uptake of fluorescent beads (Sigma, 2 μm
yellow/green fluorescent). In a first step, samples of
3*105 cells were activated with phorbol-12-myristate-13-
acetate (PMA) (0.1 μM) for 15 min at 37°C [51]. After-
wards they were incubated in 50 μl DMEM/10% FCS
together with 50 μl opsonized (FCS) beads for 48 h at
37°C, 5% CO2. The uptake of fluorescent beads was
observed qualitatively in a Zeiss Axio Observer fluores-
cence microscope. For quantitative assessment the cells
were trypsinized and resuspended in PBS (Invitrogen).
Cells were repeatedly washed and fluorescence was mea-
sured in a Beckmann Coulter FC 500.
Oxidative burst
Nitro Blue Tetrazolium (NBT)
104 cells were seeded on cover slips. They were incu-
bated with 30 μl 1 mg/ml NBT and 100 nM PMA for
45 min at 37°C and 5% CO2 [52]. Light microscope pic-
tures were taken with a Leica DM IL (Leica) using the
LAZ EZ 1.4.0 software (Leica). Pictures were brightness-
and contrast-adjusted with GIMP 2.4.5 and Power Point
(Microsoft).
Dihydrorhodamine 123 (DHR123)
3*105 Cells were incubated in PBS for 15 min at 37°C
with 0.1 μM PMA. Controls were incubated without
PMA. Afterwards, 50 μM DHR123 (Invitrogen) was
added and the cells were incubated for additional 15 min
at 37°C. The cells were fixed with 4% PFA and fluores-
cence was measured in a Beckmann Coulter FC 500.
Cell Morphology
A DM IL (Leica) and the LAZ EZ 1.4.0 software (Leica)
were used to take light microscopic pictures.
Brain slice cultures
2-3 month old C57BL/6 mice were killed by cervical dis-
location. The brain was isolated and cut into 350 μm
slices in cold preparation medium (HBSS and 10% FCS
(Invitrogen) using a Leica VT 1000 S vibratome). The
slices were transferred to an insert (Millicell CM 0.4
μm, Millipore) and cultivated with brain slice culture
medium (50% DMEM/high glucose (HyClone Labora-
tories Inc.), 25% Horse Serum (Invitrogen), 25% HBSS
(Invitrogen), 1 μg/ml insulin, 100 units/ml penicillin,
100 μg/ml streptomycin). Medium was changed every 2-
3 days. The brain slices were cultured for 9 days before
cells were seeded on them [53].
Survival and migration in brain slice cultures
Differentiated cells were labeled with DIO (Invitrogen)
for 20 min. They were added on top of the brain slices.
The viability of brain slice cultures was checked by
performing PI staining. The survival of seeded cells was
checked by adding 5 μg/ml propidium iodide to the
medium, washing and scanning the slices with a confo-
cal microscope TCS SP2 (Leica Microsystems) using the
accompanying software LCS 2.6 (Leica Microsystems).
The slices were scanned to a depth of 160 μm after 10
days of co-culture. Images were contrast- and bright-
ness-adjusted with GIMP 2.4.5 and Power Point
(Microsoft).
Statistical Analysis
All data are presented as means ± SE. Statistic analysis
were made using SigmaPlot 10.0/SigmaStat 3.5 software
(SYSTAT, Erkrath, Germany).
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